about
Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophyMyotonic disorders: A review articleCongenital and childhood myotonic dystrophy: Current aspects of disease and future directionsTaurine: the appeal of a safe amino acid for skeletal muscle disordersThe non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment.Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol.An interactive voice response diary for patients with non-dystrophic myotonia.Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trialThe potential health benefits of taurine in cardiovascular diseaseMyotonic dystrophy: therapeutic strategies for the future.Therapeutic potential of splice-switching oligonucleotides.Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias.The diagnosis and treatment of myotonic disorders.Mutational consequences of aberrant ion channels in neurological disorders.Skeletal muscle na channel disorders.Nondystrophic myotonia: challenges and future directions.Taurine: A Potential Ergogenic Aid for Preventing Muscle Damage and Protein Catabolism and Decreasing Oxidative Stress Produced by Endurance Exercise.In vivo evaluation of antimyotonic efficacy of β-adrenergic drugs in a rat model of myotonia.
P2860
Q24679378-204D6A64-D078-4B6A-A813-B9C7D060D250Q26747746-77AACC1E-47F1-4C82-8CD5-C8977AEBE516Q26777206-70AC19EE-B5AB-4ECF-B514-9007C468F788Q26799770-4329B66A-ADFB-4F2A-A6C8-4010535AE773Q33570009-757305A2-37FE-4CC2-AFB7-9B4DE751550AQ33853335-F059A971-7D43-4CC1-B0B8-E98744218B19Q35532209-71412789-31C7-40E4-B39C-EDC626D01378Q35601160-FBFD7975-E6CD-4224-8360-41998567EA4BQ36587149-6BD0D426-E306-4C5C-8DBE-5DF95243ED6DQ36981302-3B0F8EC9-0D44-4047-83AD-1088F65A5EFAQ37329544-5E64E661-F1A0-49A4-8C47-C6593F2181A6Q37363171-48926E53-14D6-4C36-B42E-83471276E3A4Q37390029-4DCA5CDC-44FF-4319-9F2C-8382FC41948BQ38093802-85AB3AD5-D0EB-4E24-833B-CBCD8D79B45DQ38239544-0C08A467-B954-4DCA-BA78-5CD5016E6362Q38698910-94579D37-EE8A-412A-8CE9-7AEE8E978E89Q39289663-9749550A-D8A2-499A-A0C7-FF398549A434Q41867028-80AF1D89-6B0E-4FE1-82DF-8896511229CCQ42742246-3BF3C336-4739-40BD-91F9-370356D05245
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Drug treatment for myotonia
@ast
Drug treatment for myotonia
@en
Drug treatment for myotonia
@en-gb
Drug treatment for myotonia
@nl
type
label
Drug treatment for myotonia
@ast
Drug treatment for myotonia
@en
Drug treatment for myotonia
@en-gb
Drug treatment for myotonia
@nl
prefLabel
Drug treatment for myotonia
@ast
Drug treatment for myotonia
@en
Drug treatment for myotonia
@en-gb
Drug treatment for myotonia
@nl
P2093
P2860
P1476
Drug treatment for myotonia
@en
P2093
B G M van Engelen
P2860
P304
P356
10.1002/14651858.CD004762.PUB2
P50
P577
2006-01-25T00:00:00Z